Mizuho Reiterates Neutral Rating on Charles River Laboratories International, Inc. (CRL)

Market Context

Charles River Laboratories International, Inc. operates in the Healthcare sector. The stock currently trades at $229.75 with a market capitalization of $9.6B. The stock has gained 38.9% over the past 52 weeks.

Analyst coverage from Mizuho provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Charles River Laboratories International, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Charles River Laboratories International, Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 13, 2026	Mizuho	Neutral	N/A
Jul 09, 2026	Morgan Stanley	Overweight	N/A
Jun 17, 2026	Morgan Stanley	Overweight	N/A
May 29, 2026	CLSA	Outperform	N/A
May 08, 2026	Evercore ISI Group	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View CRL Stock Page